Fas-associated phosphatase 1 mediates Fas resistance in myeloid progenitor cells expressing the Bcr–abl oncogene

References

• Driggers PH, Ennist DL, Gleason SL, . An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1990;87:3743–3747.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Nagel S, Proba J, . Lack of interferon consensus sequence binding protein transcripts in human myeloid leukemias. Blood 1998;91:22–29.
   PubMed Web of Science ®Google Scholar
• Holtschke T, Lohler J, Kanno J, . Immuno-deficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996;87:307–315.
   PubMed Web of Science ®Google Scholar
• Eklund EA, Jalava A, Kakar R.The transcription factors PU.1, IRF-1 and ICSBP cooperate to increase gp91-phox expression. J Biol Chem 1998;273;13957–13965.
   PubMed Web of Science ®Google Scholar
• Eklund EA, Kakar R.Recruitment of CREB-binding protein by PU.1, IFN-regulatory factor 1, and the IFN consensus sequence-binding protein is necessary for IFNγ induced p67phox and gp91phox expression. J Immunol 1999;163:6095–6105.
   PubMed Web of Science ®Google Scholar
• Huang W, Zhu C, Wang H, . The interferon consensus sequence binding protein (ICSBP/IRF8) represses PTPN13 gene transcription in differentiating myeloid cells. J Biol Chem 2008;283:7921–7935.
   PubMed Web of Science ®Google Scholar
• Huang W, Zhou W, Saberwal G, . Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription. Mol Cell Biol 2010;30:4575–4594.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Hochhaus A, Nitsche A, . Expression of ICSBP in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response. Blood 2001;97:3648–3650.
   PubMed Web of Science ®Google Scholar
• Oncomine research edition.Ann Arbor, MA: University of Michigan. Available from: www.oncomine.org
   Google Scholar
• Konieczna I, Horvath E, Wang H, . Constitutive activation of SHP2 cooperates with ICSBP-deficiency to accelerate progression to acute myeloid leukemia. J Clin Invest 2008;118:853–867.
   PubMed Web of Science ®Google Scholar
• Zhang X, Ren R.Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998, 92:3829–3840.
   PubMed Web of Science ®Google Scholar
• Hao SX, Ren R.Expression of ICSBP is down-regulated in bcr-abl-induced murine CML-like disease and forced co-expression of ICSBP inhibits bcr-abl-induced MPD. Mol Cell Biol 2000;20:1149–1161.
   PubMed Web of Science ®Google Scholar
• Zhu CL, Saberwal G, Lu YF, . The interferon consensus sequence binding protein (ICSBP) activates transcription of the gene encoding Neurofibromin 1 (NF1). J Biol Chem 2004;279:50874–50885.
   PubMed Web of Science ®Google Scholar
• Saras J, Claesson-Welsh L, Heldin CH, . Cloning and characterization of PTPL1, a PTP with similarities to cytoskeletal-associated proteins. J Biol Chem 1994;269:24082–24089.
   PubMed Web of Science ®Google Scholar
• Yanagisawa J, Takahashi M, Kanki H, . The molecular interaction of Fas and Fap1. J Biol Chem 1997;272:8539–8545.
   PubMed Web of Science ®Google Scholar
• Roeder I, Horn M, Glauche I, . Dynamic modeling of imatinib-treated CML: functional insights & clinical implications. Nat Med 2006;12:1181–1184.
   PubMed Web of Science ®Google Scholar
• Michor F, Hughes TP, Iwasa Y, . Dynamics of CML. Nature 2005;435:1267–1270.
   PubMed Web of Science ®Google Scholar
• Larrick JW, Fischer DG, Anderson SJ, . Characterization of a human macrophage-like cell line stimulated to differentiate in vitro: a model of macrophage functions. J Immunol 1980;125:6–12.
   PubMed Web of Science ®Google Scholar
• Wang H, Lindsey S, Konieczna I, . Constitutively active SHP2 cooperates with HoxA10-overexpression to induce AML. J Biol Chem 2009;284:2549–2567.
   PubMed Web of Science ®Google Scholar
• Huang W, Hu L, Bei L, . The leukemia-associated fusion protein Tel-platelet-derived growth factor receptor β (Tel-PdgfRβ) inhibits transcriptional repression of PTPN13 gene by interferon consensus sequence binding protein (Icsbp). J Biol Chem 2012;287:8110–8125.
   PubMed Web of Science ®Google Scholar
• Eisterer W, Jiang X, Christ O, . Different subsets of primary CML stem cells engraft immuno-deficient mice and produce a model of the human disease. Leukemia 2005;19:435–441.
   PubMed Web of Science ®Google Scholar
• Jamieson CHM, Ailles LE, Dylla SJ, . Granulocyte-macrophage progenitors as candidate leukemia stem cells in blast crisis CML. N Engl J Med 2004;351:657–667.
   PubMed Web of Science ®Google Scholar
• Minami Y, Stuart SA, Ikawa T, . Bcr/abl-transformed GMP as myeloid leukemia stem cells. Proc Natl Acad Sci USA 2008;105: 17967–17972.
   PubMed Web of Science ®Google Scholar
• Drucker BJ, Guilhot F, O’Brien SG, . Five-year follow up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• Okimoto RA, Van Etten R.Road toward optimal initial therapy for chronic myeloid leukemia. Cur Opin Hematol 2011;18:89–97.
   PubMed Web of Science ®Google Scholar
• Cortes J, Hochhaus A, Hughes T, . Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 2011;29:524–531.
   PubMed Web of Science ®Google Scholar
• Mitchell B, Deninger M.Risk stratification in newly diagnosed CML. Leuk Lymphoma 2011;52:4–11.
   PubMed Web of Science ®Google Scholar
• Miething C, Grundler R, Mugler C, . Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. Proc Natl Acad Sci USA 2007;104:4594–4599.
   PubMed Web of Science ®Google Scholar
• Turkina AG, Logacheva NP, Stromskaya TP, . Studies of some mechanisms of drug resistance in CML. Adv Exp Med Biol 1999;457:477–488.
   PubMed Web of Science ®Google Scholar
• Kim KM, Lee K, Hong YS, . Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells. Exp Mol Med 2000;32:246–254.
   PubMed Web of Science ®Google Scholar
• Lickliter JD, Kratzke RA, Nguyen PL, . Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. Exp Hematol 1999;27:1519–1527.
   PubMed Web of Science ®Google Scholar
• Liu WH, Cheng YC, Chang LS.ROS-mediated p38alpha MAPK activation and ERK inactivation responsible for upregulation of Fas and FasL and autocrine Fas-mediated cell death in phospholipase A(2)-treated U937 cells. J Cell Physiol 2009;219:642–651.
   PubMed Web of Science ®Google Scholar
• Xiao ZY, Wu W, Eagleton N, . Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin. World J Gastroenterol 2010;16: 112–118.
   PubMed Web of Science ®Google Scholar
• Yao H, Song E, Chen J, . Expression of Fap1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer. Br J Cancer 2004;91:1718–1725.
   PubMed Web of Science ®Google Scholar